clinical trials

Axsome Therapeutics will report first-quarter 2026 financial results on May 4, 2026, with management conference call at 8:00 a.m. ET.

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.

Fortrea unveiled Fortrea Intelligent Technology, an AI-powered suite automating clinical trial workflows and enhancing productivity for research centers and investigators.

Fortrea unveiled Fortrea Intelligent Technology, an AI-driven solution suite designed to automate workflows and provide real-time insights across clinical trial operations.

Fortrea launches AI-powered clinical trial platform FIT to automate operations and accelerate drug development timelines for pharmaceutical sponsors and research sites globally.

Over 30 pharma companies develop 35+ severe asthma drugs with recent approvals validating new mechanisms, signaling major market opportunity and competitive intensity ahead.

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud over misleading statements about relacorilant clinical trials and FDA approval prospects.

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.

Telix Pharma reports 11% Q1 revenue growth to US$230M, reaffirms FY guidance, while advancing prostate and brain cancer pipelines through Phase 3 and regulatory milestones.

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.

IMN market expected to grow nearly 8x from $130M in 2025 to $1B by 2036, driven by novel therapies addressing unmet treatment needs.

Rosen Law Firm solicits Corcept investors in securities class action over alleged misstatements regarding relacorilant clinical trials and FDA approval prospects.

Class action lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug's clinical strength and FDA approval prospects.

Schall Law Firm launches class action against $ALDX over alleged false statements regarding reproxalap drug candidate. Investors who bought securities Nov 2023-Mar 2026 can join before May 29 deadline.

Rosen Law Firm files securities class action against $ALDX over alleged misleading statements regarding reproxalap clinical trial results. Lead plaintiff deadline set for May 29, 2026.

Corcept Therapeutics faces class action lawsuit alleging misrepresentation of relacorilant clinical trial data and FDA approval prospects. Investors from Oct 2024-Dec 2025 may seek compensation.

Spinal cord injury market projected to grow from $354M to $1.4B by 2034 as six emerging therapies target previously untreated condition.

Perspective Therapeutics will present at two major investor conferences in April 2026, highlighting its alpha-emitting radiopharmaceutical pipeline for oncology.

XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.